{"id":7395,"date":"2011-04-03T17:56:36","date_gmt":"2011-04-03T21:56:36","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=7395"},"modified":"2011-07-19T17:44:29","modified_gmt":"2011-07-19T21:44:29","slug":"2-year-outcomes-of-the-resolute-all-comers-trial","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2011\/04\/03\/2-year-outcomes-of-the-resolute-all-comers-trial\/","title":{"rendered":"2-Year Outcomes of the RESOLUTE All Comers Trial"},"content":{"rendered":"<p>The Resolute zotarolimus-eluting stent (ZES) is now starting to  demonstrate good long-term results. At an interventional featured  clinical study session at the ACC in New Orleans and in a simultaneous<a href=\"http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736%2811%2960395-4\/fulltext\"> publication in the<em> Lancet<\/em><\/a>, Sigmund Silber and colleagues  presented the 2-year findings of the RESOLUTE All Comers trial  comparing the ZES with the Xience V everolimus-eluting stent (EES) in a  broadly representative patient population. Previously, the 1-year  results had shown that the ZES was noninferior to the EES with respect  to the primary endpoint of cardiac death, target vessel MI, and ischemia-driven target lesion revascularization.<\/p>\n<p>More than 2200 patients at 17 centres in Europe and Israel completed the 2-year  follow-up. Patient-related events (all deaths,\u00a0 MIs, and  revascularizations) occurred equally in both groups (20.6% of the ZES  group and 20\u00b75% of the EES group). Similarly, stent-related events (target lesion failure) occurred in 11\u00b72% of the ZES group and 10\u00b77%  of the EES group (p=0\u00b7736). Three patients in each group had a stent  thrombosis after 1 year.<\/p>\n<p>The investigators point out that &#8220;the greater number of  patient-related than stent-related events in patients with complex  clinical and lesion characteristics emphasises that during long-term  follow-up, the optimisation of secondary prevention is at least as  important as the selection of which new generation drug-eluting stent to  implant in a specific lesion.&#8221;<\/p>\n<p>In an <a href=\"http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736%2811%2960468-6\/fulltext\">accompanying comment<\/a>, Jens Lassen writes that &#8220;the most  important take-home message of  the 2-years result of the RESOLUTE All  Comers trial is that the overall  non-inferiority result was preserved  even after cessation of dual  antiplatelet therapy, and that the low  rate of very late stent  thrombosis seems to be achieved without a major  increase in late target  lesion revascularisations.\u201d<\/p>\n<p><em>For more of our ACC.11 coverage of late-breaking clinical trials,  interviews with the authors of the most important research, and blogs  from our fellows on the most interesting presentations at the meeting,  check out our <a href=\"..\/acc-11-cardioexchange-coverage-roundup\/\">Coverage Roundup<\/a>.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Resolute zotarolimus-eluting stent (ZES) is now starting to demonstrate good long-term results. At an interventional featured clinical study session at the ACC in New Orleans and in a simultaneous publication in the Lancet, Sigmund Silber and colleagues presented the 2-year findings of the RESOLUTE All Comers trial comparing the ZES with the Xience V [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[777,437,776],"class_list":["post-7395","post","type-post","status-publish","format-standard","hentry","category-interventional-cardiology","tag-everolimus-eluting-stent","tag-stents","tag-zotaralimus-eluting-stent"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/7395","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=7395"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/7395\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=7395"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=7395"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=7395"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}